地西他滨联合阿糖胞苷对HL60细胞的增殖抑制作用研究  

Experimental study of decitabine in combination with cytarabine inhibiting the growth of human leukemia HL60 cells in vitro

作　　者：谢月[1] 李砚如 赵慧慧[1] 黄佳瑜[1] 连芸[1] 朱雨[1] 洪鸣[1] 朱晗[1] 钱思轩[1] 

机构地区：[1]江苏省人民医院、南京医科大学第一附属医院血液科,南京210029

出　　处：《临床血液学杂志》2017年第3期364-367,共4页Journal of Clinical Hematology

基　　金：国家自然科学基金(No:81570143、81270614、81070437)

摘　　要：目的:研究地西他滨(DAC)和阿糖胞苷(Ara-C)单用或联合作用对人急性髓细胞白血病HL60细胞增殖的影响,并探讨最佳的联合给药方式。方法:将不同浓度的DAC和Ara-C分别单独或联合作用于HL60细胞,采用CCK8法检测2种药物单独或联合作用对HL60细胞增殖的影响,采用金(正均)氏公式计算协同系数Q值分析两药的协同作用。结果:DAC和Ara-C单独作用时对HL60细胞增殖的抑制作用均呈剂量依赖关系,DAC(0.13~2.00μmol/L)序贯Ara-C联用对HL60细胞增殖抑制有协同作用(Q值为1.20~1.54),并呈剂量依赖性。DAC同时联合Ara-C或Ara-C序贯DAC无协同作用,甚至为拮抗作用(Q值<1.15)。且DAC序贯Ara-C对HL60细胞的增殖抑制率明显高于DAC同时联合Ara-C或Ara-C序贯DAC(P<0.05)。结论:DAC序贯Ara-C可协同抑制HL60细胞增殖,该方案明显优于DAC与Ara-C同时用药组或Ara-C序贯DAC组。DAC48h后序贯Ara-C联合方案在急性髓细胞白血病的治疗中可能具有重要临床意义。Objective：To investigate the inhibitory effects of decitabine （DAC）,cytarabine （Ara-C） and their combination on the proliferation of human acute myeloid leukemia HL60 cells in vitro, and to explore the best drug regimen. Method：The cell proliferation inhibitory rates of HL60 cells treated with different concentrations of DAC and Ara-C alone and given either simuhaneously or sequentially were detected by CCK8 assay. King formula was used to determine if there was a synergistic effect of DAC in combination with Ara-C. Result： Both DAC and Ara-C as single agent had dose-dependent effects of proliferation inhibition on HL60 cells. DAC （0.13 to 2.00 μmol/L） prior to Ara-C had a synergistic effect on proliferation inhibition （Q value was 1.20 to 1.54）. DAC and Ara-C giv en simultaneously and Ara-C prior to DAC had no synergistic effect, or even antagonism （Q value〈1.15）. DAC prior to Ara-C showed the highest proliferation inhibition rate compared with DAC and Ara-C given simuhaneously and Ara-C prior to DAC （P〈0.05）. Conclusion：DAC followed by Ara C is a best synergistic combination in HL60 cell line compared with DAC and Ara-C given simultaneously and Ara-C prior to DAC. It suggests that DAC followed by Ara-C48 hours later may have great clinical potential in the treatment of acute myeloid leukemia.

关 键 词：地西他滨 阿糖胞苷 白血病 髓细胞 急性 

分 类 号：R733.71[医药卫生—肿瘤]